2022 FDA TIDES (Peptides and Oligonucleotides) Harvest

A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-02, Vol.16 (3), p.336
Main Authors: Al Musaimi, Othman, Al Shaer, Danah, Albericio, Fernando, de la Torre, Beatriz G
Format: Article
Language:English
Subjects:
Amino acids
Amyloidosis
Chemical properties
Diabetes
Drug dosages
drugs
Dyspnea
FDA
FDA approval
gadopiclenol
Identification and classification
Ligands
Magnetic resonance imaging
Molecular weight
Oligonucleotides
Opinion
Peptides
Pharmaceutical industry
Proteins
Structure
Vitamin A
vutrisiran
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph16030336